Granahan Investment Management LLC Sells 65,175 Shares of Repligen Corporation $RGEN

Granahan Investment Management LLC trimmed its position in Repligen Corporation (NASDAQ:RGEN) by 48.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,871 shares of the biotechnology company’s stock after selling 65,175 shares during the quarter. Granahan Investment Management LLC’s holdings in Repligen were worth $9,340,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fred Alger Management LLC boosted its stake in Repligen by 19.7% during the third quarter. Fred Alger Management LLC now owns 358,422 shares of the biotechnology company’s stock worth $47,910,000 after buying an additional 58,866 shares in the last quarter. Cinctive Capital Management LP acquired a new position in shares of Repligen in the 3rd quarter valued at $3,398,000. Bamco Inc. NY raised its stake in shares of Repligen by 39.1% in the 3rd quarter. Bamco Inc. NY now owns 381,678 shares of the biotechnology company’s stock valued at $51,019,000 after buying an additional 107,235 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Repligen by 3.3% during the 3rd quarter. California Public Employees Retirement System now owns 70,252 shares of the biotechnology company’s stock worth $9,391,000 after acquiring an additional 2,263 shares during the period. Finally, Bank of Nova Scotia lifted its holdings in shares of Repligen by 28.1% during the 3rd quarter. Bank of Nova Scotia now owns 40,657 shares of the biotechnology company’s stock worth $5,437,000 after acquiring an additional 8,910 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Trading Up 0.4%

Shares of Repligen stock opened at $114.20 on Monday. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $175.77. The stock has a market capitalization of $6.43 billion, a P/E ratio of 134.35, a price-to-earnings-growth ratio of 2.23 and a beta of 1.15. The company has a 50-day simple moving average of $145.43 and a 200 day simple moving average of $147.05. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RGEN. Wells Fargo & Company decreased their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group lowered their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Finally, KeyCorp reissued an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $174.58.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.